Австралия - английски - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; indigo carmine; oxidised maize starch; rice starch - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; rice starch; magnesium stearate; hydrolysed maize starch; povidone; indigo carmine; oxidised maize starch - congestive heart failure - sigmaxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. sigmaxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because sigmaxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - sigmaxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

САЩ - английски - NLM (National Library of Medicine)

bryant ranch prepack - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug

САЩ - английски - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 250 ug - heart failure: digoxin is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. atrial fibrillation: digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin.

САЩ - английски - NLM (National Library of Medicine)

lannett company, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug - heart failure: digoxin is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. atrial fibrillation: digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. digitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to digoxin. a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin.

САЩ - английски - NLM (National Library of Medicine)

mckesson contract packaging - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug

САЩ - английски - NLM (National Library of Medicine)

dept health central pharmacy - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 125 ug

Ирландия - английски - HPRA (Health Products Regulatory Authority)

correvio (uk) ltd - tirofiban hydrochloride monohydrate - concentrate for soln for inf - 250 microgram/ml

Ирландия - английски - HPRA (Health Products Regulatory Authority)

mundipharma pharmaceuticals limited - fluticasone propionate; formoterol fumarate dihydrate - pressurised inhalation, suspension - 250 µg/10 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and fluticasone

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - digoxin - oral tablet - 62.5microgram